Intrinsiqq
Aura Biosciences Inc. logo

Aura Biosciences Inc. Insider Trading

AURA

Compare
Last 12 months

Insiders sold 903K and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Senior Vice President, Finance Amy Elazzouzi sold 43K on Feb 17, 10% of their stake, outside a plan. The last open-market buy by an executive or director was in May 2025.

Net open-market
−903K
0 buys · 10 sales
Under a 10b5-1 plan
0%
of the value sold
Insiders who bought / sold
0 / 6
executives and directors
Last open-market buy
May 2025
May 16, 2025

Get an email when AURA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Nov 16No plan
    Janet Jill Hopkins
    Chief Medical Officer · sold 16,903 at $7.05
    119K
    4.4% of stake
  • Jun 16No plan
    Anthony S Gibney
    See Remarks · sold 12,824 at $6.42
    82K
    4.6% of stake
  • May 7No plan
    Matrix Capital Management Company, LP
    Large holder · sold 6,922,870 at $5.64
    $39M
    100% of stake
  • Apr 16No plan
    Conor Kilroy
    See Remarks · sold 11,738 at $7.02
    82K
    5.1% of stake
  • Feb 17No plan
    Conor Kilroy
    See Remarks · sold 12,079 at $5.05
    61K
    6.7% of stake
  • Feb 17No plan
    Mark Plavsic
    Chief Technology Officer · sold 15,890 at $5.05
    80K
    8.1% of stake
  • Feb 17No plan
    Janet Jill Hopkins
    Chief Medical Officer · sold 20,401 at $5.06
    103K
    8.1% of stake
  • Feb 17No plan
    Amy Elazzouzi
    Senior Vice President, Finance · sold 8,549 at $5.06
    43K
    10% of stake
  • Feb 17No plan
    Pinos Elisabet De Los
    See Remarks · sold 47,648 at $5.06
    241K
    8.1% of stake
  • Jan 20No plan
    Amy Elazzouzi
    Senior Vice President, Finance · sold 1,581 at $4.86
    8K
    1.8% of stake
  • Jan 20No plan
    Pinos Elisabet De Los
    See Remarks · sold 16,928 at $4.86
    82K
    2.8% of stake
  • Nov 17, 2025No plan
    Janet Jill Hopkins
    Chief Medical Officer · sold 17,109 at $5.42
    93K
    6.3% of stake
  • Oct 29, 2025No plan
    Amy Elazzouzi
    Senior Vice President, Finance · sold 896 at $6.35
    6K
    1.0% of stake
  • Oct 29, 2025No plan
    Pinos Elisabet De Los
    See Remarks · sold 9,049 at $6.35
    57K
    1.5% of stake
  • Oct 16, 2025No plan
    Mark Plavsic
    Chief Technology Officer · sold 12,169 at $6.35
    77K
    5.8% of stake
  • Aug 18, 2025No plan
    Amy Elazzouzi
    Senior Vice President, Finance · sold 7,722 at $6.70
    52K
    8.2% of stake
  • May 16, 2025
    David Michael Johnson
    Director · bought 20,000 at $4.90
    98K
    4.6% of stake
  • May 16, 2025No plan
    Anthony S Gibney
    See Remarks · sold 1,519 at $5.15
    8K
    2.6% of stake
  • May 16, 2025
    Anthony S Gibney
    See Remarks · bought 50,000 at $4.90
    245K
    721% of stake
  • Apr 16, 2025No plan
    Amy Elazzouzi
    Senior Vice President, Finance · sold 897 at $5.49
    5K
    1.1% of stake
  • Apr 16, 2025No plan
    Conor Kilroy
    See Remarks · sold 7,162 at $5.49
    39K
    3.8% of stake
  • Feb 18, 2025No plan
    Mark Plavsic
    Chief Technology Officer · sold 2,151 at $7.75
    17K
    1.0% of stake
  • Feb 18, 2025No plan
    Amy Elazzouzi
    Senior Vice President, Finance · sold 1,404 at $7.75
    11K
    1.7% of stake
  • Feb 18, 2025No plan
    Janet Jill Hopkins
    Chief Medical Officer · sold 2,534 at $7.75
    20K
    0.9% of stake
  • Feb 18, 2025No plan
    Pinos Elisabet De Los
    See Remarks · sold 20,221 at $7.75
    157K
    3.2% of stake
  • Jan 21, 2025No plan
    Pinos Elisabet De Los
    See Remarks · sold 15,955 at $7.67
    122K
    3.5% of stake
  • Jan 21, 2025No plan
    Amy Elazzouzi
    Vice President, Finance · sold 1,001 at $7.67
    8K
    2.5% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch AURA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with AURA

CompareIntrinsic value
CELZCreative Medical Technology Holdings Inc.
$0.40-8.14%10
VCELVericel Corporation
$57.52-1.27%65
IOVAIovance Biotherapeutics, Inc.
$6.90-5.61%10
CGONCG Oncology, Inc.
$79.47-2.97%40
TECHBio-Techne Corporation
$72.67-0.04%41
MRNAModerna, Inc.
$195.00-2.17%13
HALOHalozyme Therapeutics Inc.
$91.35-1.82%70
SCLXScilex Holding Company
$0.57-12.95%0

Held by ETFs

AURA is in 13 US ETFs. The largest of them, with AURA's weight in each:

Spot a number that looks wrong? Check it in AURA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing AURA

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.